Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both ...

Regeneron acquired a promising weight management asset that could become lucrative. Shares of Regeneron (NASDAQ: REGN) have declined this year due to issues with one of its former growth drivers, ...

Starting July 1, Zepbound will no longer be preferred ... Novo and Lilly have been locked in a fierce competition to dominate the obesity market, which is expected to reach $130 billion by the ...

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for ... it will also be adding two new doses, as competition in the space continues to heat ...

CVS' announcement overshadowed a strong Q1 earnings report from Lilly and immediately raised concerns from analysts and investors worried about direct competition in the market between Zepbound ...

such as Ozempic and Zepbound. Some economists and talking heads insist that the highly regulated healthcare sector is immune to price signals and other market dynamics due to its unique structure ...

Even more damaging has been competition from Eli Lilly, the maker of the drug sold as Mounjaro and Zepbound. Novo Nordisk had a head start, winning approval to market its drug for obesity more ...

The next section, “Zepbound coupons and savings,” includes ... After that, other drugmakers can create generic versions. This competition in the market can lead to lower costs for generics.

Lilly and Novo Nordisk NVO presently dominate the market. Mounjaro and Zepbound face strong competition from Novo Nordisk’s semaglutide medicines, Ozempic for diabetes and Wegovy for obesity.

The therapy is facing stiff competition, biosimilar and otherwise, that is eating into its market share ... only approved medicine that does that is Zepbound, the weight loss therapy marketed ...